Your Pet’s Cells Are Running Out of Fuel — Here’s What That Means

At a Glance

Your senior dog or cat is not just getting older — their cells are running out of the fuel they need to repair damage, produce energy, and keep working properly. That fuel has a name: NAD+ (nicotinamide adenine dinucleotide). It powers hundreds of cellular processes, from DNA repair to mitochondrial function, and it declines with age in every mammal studied so far. This article is the practical companion to our guide on the 12 Hallmarks of Ageing. Where that article explained what goes wrong as pets age, this one explores what emerging science, and some well-established veterinary tools, can do about it. We cover NAD+ precursors like NMN and NR, the glutathione system (including SAMe and NAC, two supplements your vet may already use), mitochondrial cofactors like CoQ10, L-carnitine, and C8/C10 MCTs for cognitive support, and emerging interventions like urolithin A, astaxanthin, PQQ, and spermidine. Some of what follows is backed by strong veterinary evidence — decades of it. Some is extrapolated from human and rodent research. We will always tell you which is which. And one compound in this article is safe for dogs but genuinely dangerous for cats, a reminder that what helps one species can harm another.

None of this replaces your vet. Every intervention discussed here should be a conversation between you and your veterinary team, not something you start on
your own.

The Full Guide

The Currency Your Pet’s Cells Are Losing

Pet parents often search for: ‘NAD+ for dogs,’ ‘cellular energy senior pets,’ or ‘why do pets age.’ Here is what the evidence says.

Every cell in your dog’s or cat’s body runs on a molecule called NAD+, which stands for nicotinamide adenine dinucleotide. It is not a vitamin, not a mineral, and not something you will find on a supplement label in most pet shops. But it is arguably the single most important molecule in cellular metabolism, required by over 500 enzymes for tasks ranging from converting food into energy to repairing broken DNA.

NAD+ works through three major pathways. It feeds the electron transport chain in mitochondria, the structures inside cells that generate ATP, the body’s universal energy currency. It fuels PARPs, the enzymes that rush to repair DNA damage every time a strand breaks. And it powers a family of seven enzymes called sirtuins, the master regulators of cellular maintenance, inflammation control, and genomic stability.

The problem is simple and well-documented in humans and rodents: NAD+ levels fall with age. The decline is driven from both sides — the enzymes that make NAD+ (particularly one called NAMPT) become less active, while the enzymes that consume it (particularly CD38, which rises with chronic inflammation) become more active. The result is a cell with less fuel for repair, less fuel for energy production, and less fuel for the maintenance enzymes that keep everything running.

An important caveat: this NAD+ decline has been directly measured in ageing human and rodent tissues including heart, brain, liver, skeletal muscle, and skin. In dogs, reduced NAD+ has been documented in diseased muscle tissue, but not yet in a published study of healthy ageing companion dogs. In cats, the direct evidence is essentially absent. The story is strongly suggested by the broader mammalian biology, but intellectual honesty requires us to say: it is inferred in companion animals, not yet proven.

The Seven Mechanics Inside Every Cell

Sirtuins are the reason NAD+ decline matters. Think of them as seven specialised mechanics stationed inside every cell, each with a different job. SIRT1 tunes metabolic responses and controls inflammation. SIRT3 maintains mitochondrial protein quality. SIRT6, the one researchers call the “longevity gene”, repairs DNA double-strand breaks, maintains telomeres, and keeps silent regions of the genome from reactivating.

All seven sirtuins are NAD+-dependent. They consume NAD+ as a co-substrate every time they work, meaning they compete for the same declining fuel pool as PARPs and CD38. When NAD+ falls, the mechanics start cutting corners. DNA damage accumulates. Mitochondria become less efficient. Inflammation rises. Retrotransposons, ancient viral sequences embedded in the genome that SIRT6 normally keeps silenced, begin reactivating, driving further inflammation.

The most striking finding in comparative biology comes from researchers at the University of Rochester who studied DNA repair efficiency across 18 rodent species spanning lifespans of 3 to over 30 years. They found that repair efficiency correlated tightly with maximum lifespan, and the dominant determinant was not how much SIRT6 each species made but how potent each species’ SIRT6 protein was. The beaver’s SIRT6 was substantially more enzymatically active than the mouse’s. Long-lived species, it appears, have evolved a more powerful version of this one critical mechanic.

Our dogs and cats have not had the evolutionary pressure to develop beaver-grade SIRT6. But supporting NAD+ availability, keeping the fuel tank as full as possible, is the lever we have to keep the SIRT6 they do have working.

Putting Fuel Back — NMN and NR

If you have been reading about NAD+ supplements for pets, you have probably encountered NMN and NR. Here is what the veterinary evidence actually shows.

NMN (nicotinamide mononucleotide) and NR (nicotinamide riboside) are the two leading NAD+ precursors, molecules the body converts into NAD+ through the salvage pathway (the dominant NAD+-production route in adult mammals). NMN is one biochemical step from NAD+; NR is two steps away, requiring phosphorylation by enzymes called NRK1 and NRK2 before becoming NMN and then NAD+.

That description makes NMN sound closer to the finish line — and this is exactly how most supplement marketing frames it. But the reality is more nuanced, and the scientific community is genuinely divided on whether this one-step advantage translates into a meaningful clinical difference.

NMN: The Evidence in Dogs

NMN has the strongest evidence base of any NAD+ precursor in dogs, which is worth stating clearly — even though “strongest” still means a small number of studies. A 2020 subacute toxicity study published in Frontiers in Pharmacology gave oral NMN to Beagle dogs twice daily for 14 days. The compound was well tolerated, with only mild rises in serum creatinine and uric acid at very high doses. This is a safety study, not an efficacy study, but it established that oral NMN does not cause obvious harm in dogs at substantial doses.

The more important study was a 2024 randomised, double-blind, placebo-controlled trial published in Scientific Reports. Seventy senior dogs with mild-to-moderate cognitive impairment received either a placebo or a combination product containing an NAD+ precursor and a senolytic (a compound that clears damaged, non-functioning cells). Dogs in the full-dose group showed significant improvement in pet-parent-rated cognitive function compared to the placebo group. Trends toward improved activity levels, reduced frailty, and increased pet-parent-reported
happiness were also observed.

The caveats matter: the cognitive improvement was pet-parent-reported, not measured by in-clinic testing (which showed no significant difference). The product was a combination, so the NAD+ precursor’s individual contribution cannot be isolated from the senolytic. And this is a single trial awaiting replication. But it is the strongest published randomised controlled trial of any longevity supplement in companion dogs, and the quality-of-life signal, not just lifespan, but healthspan — is exactly the frame that matters.

NR: The Quieter Sibling

NR (nicotinamide riboside) is biochemically upstream of NMN but may be functionally equivalent, or even superior, in terms of cellular delivery. The reason: there is a genuine scientific debate about whether intact NMN molecules can enter cells directly.

One research group reported in 2019 that a transporter called Slc12a8 can shuttle intact NMN across cell membranes. Another group published a rebuttal in the same journal arguing that the experiments showed cell-surface association rather than genuine internalisation, and that NMN must be dephosphorylated to NR by an enzyme called CD73 before crossing membranes, then re-phosphorylated inside the cell. This debate remains unresolved. If the second interpretation is correct, oral NMN’s mechanism of action is functionally the same as oral NR’s.

NR has no dedicated canine efficacy trial. Its evidence base in humans is stronger than NMN’s, with multiple randomised controlled trials demonstrating it raises blood and tissue NAD+ and is well-tolerated, but translation to dogs and cats is inferred, not documented.

NMN and NR in Cats

There are zero peer-reviewed intervention studies of either NMN or NR in cats. This is a hard fact. Consumer anecdotes circulate online (individual cats whose owners report improvements), but single uncontrolled cases are not evidence. The feline NAD+ precursor story is entirely extrapolated from rodent and limited canine work.

One reassuring note: cats’ well-known metabolic vulnerability (the UGT1A6 glucuronidation deficiency that makes acetaminophen lethal) does not directly affect NMN or NR. These are endogenous nucleotide-pathway molecules, not phenolic xenobiotics. However, cats do have lower overall hepatic conjugation capacity and uniquely reactive haemoglobin, which means purity and quality of any supplement given to a cat matters more than it does for dogs.

Forms and Quality

For NMN, the biologically active form is β-NMN (beta-NMN); the isomeric impurity α-NMN has no known biological role. Quality products should be ≥99% β-NMN, verified by third-party HPLC testing. NMN is hygroscopic and heat-sensitive, so cool, dry storage matters. Liposomal and sublingual formulations claim improved absorption but lack peer-reviewed head-to-head bioavailability data in dogs or cats.

For NR, the dominant commercial form is NR chloride, most widely known under a patented name. NR tartrate is an alternative salt with comparable properties. NR is more stable than NMN in solid form and has a longer shelf life at room temperature.

The practical takeaway: the choice between NMN and NR is currently more about formulation quality and product trust than about mechanism. Neither has a definitive advantage in companion animals based on published evidence.

The Master Antioxidant — Glutathione and Its Partners

Pet parents often search for: ‘glutathione for cats,’ ‘SAMe for dogs liver,’ ‘NAC for pets,’ or ‘antioxidant supplements senior cats.’ Here is what the evidence says.

If NAD+ is the fuel, glutathione is the fire suppression system. It is the most abundant antioxidant inside mammalian cells, a small tripeptide of three amino acids (glutamate, cysteine, and glycine) that neutralises free radicals, detoxifies harmful substances, recycles vitamins C and E, and maintains the redox balance that keeps proteins functional.

Glutathione connects to the NAD+ story through a single critical step: the enzyme glutathione reductase, which recycles oxidised glutathione (GSSG) back to its active reduced form (GSH), requires NADPH as a cofactor. NADPH is the phosphorylated reducing equivalent of NAD+. When the NAD+ pool shrinks, NADPH supply falls, glutathione recycling slows, and the cell’s antioxidant capacity drops. NAD+ and glutathione decline together, not by coincidence, but by mechanism.

The Cat Evidence: Stronger Than You Might Expect

This is the section of this article where the companion-animal evidence is genuinely strong, not extrapolated from mice, not inferred from human data. It has been directly measured in cats and dogs over two decades of published veterinary research.

A 2024 study published in the British Journal of Nutrition measured whole blood and red blood cell glutathione in senior cats (over nine years old) compared with young adult cats. Senior cats had significantly lower total, reduced, and oxidised glutathione, and the same study found that dietary glycine supplementation partially restored red blood cell glutathione levels over 12 weeks. This is published, contemporary, peer-reviewed evidence that ageing cats have measurable glutathione deficiency, and that a simple nutritional intervention can partly address it.

Earlier work confirmed the pattern across disease states. A 2009 study published in the Journal of Veterinary Internal Medicine found that clinically ill dogs and cats had reduced red blood cell glutathione compared to healthy controls. Cats with chronic kidney disease showed significantly lower glutathione ratios. Cats with feline immunodeficiency virus showed altered glutathione in T-cell populations.

The Dog Evidence: Liver Disease and Beyond

Dogs tell the glutathione story through the liver. Multiple studies spanning the 2000s from Cornell’s veterinary hepatology group documented depleted hepatic glutathione in dogs with naturally occurring chronic liver disease, steroid-induced vacuolar hepatopathy, and copper-storage hepatopathy. The 2009 Journal of Veterinary Internal Medicine study that measured glutathione in clinically ill animals found that dogs, like cats, had significantly reduced red blood cell glutathione and cysteine levels compared to healthy controls.

The canine glutathione decline is also documented in cognitive ageing. The same Beagle ageing studies at the University of Toronto and the University of California, Irvine that underpin much of this article’s cognitive-support evidence measured oxidative stress markers as part of their methodology. Senior Beagles consistently showed elevated protein carbonyls and reduced antioxidant capacity, markers that track directly with glutathione status.

Where the cat story centres on kidney disease and oxidative vulnerability, the dog story centres on liver disease and cognitive decline. Both converge on the same mechanism: glutathione falls, oxidative damage rises, and the cell’s ability to protect itself erodes.

SAMe: The Vet-Prescribed Workhorse

S-adenosylmethionine (SAMe) is the most evidence-supported glutathione intervention in veterinary medicine — and it has been for over twenty years. SAMe is a methyl donor that feeds into the transsulphuration pathway, ultimately increasing cysteine availability for glutathione synthesis while also donating methyl groups for hundreds of other biochemical reactions, including neurotransmitter metabolism.

The evidence base is multi-decade and multi-species. Studies from Cornell’s veterinary hepatology group demonstrated that SAMe supplementation increased hepatic glutathione in both normal and diseased cats and dogs. It protected against steroid-induced liver damage in dogs. It supported cognitive function in older dogs. It is the standard of care for feline and canine hepatobiliary disease across mainstream veterinary internal medicine, not alternative, not integrative; simply standard.

One formulation detail matters enormously: SAMe is extremely moisture-sensitive. Tablets must remain enteric-coated and must never be crushed, split, or removed from blister packs until the moment of administration. Bioavailability varies dramatically between products; veterinary-grade enteric-coated formulations are not interchangeable with bulk SAMe powder from a human supplement shop. This is one of the most common mistakes pet parents make with an otherwise excellent supplement.

NAC: The Precursor

N-acetylcysteine (NAC) is the acetylated form of cysteine, the rate-limiting amino acid in glutathione synthesis. It has been used in veterinary emergency medicine for decades: every small-animal hospital stocks it for acetaminophen toxicity in cats and acute liver failure in dogs. Its safety profile is well-characterised, its pharmacokinetics are published, and it is one of the most affordable glutathione- supporting interventions available.

NAC is effective but imperfect. Oral absorption is approximately 33% in cats, with a half-life of roughly 90 minutes. The sulphurous taste makes compliance difficult in many cats, a practical reality that matters more than the pharmacokinetics.

A dose-response warning: at very high doses, NAC can paradoxically act as a pro-oxidant rather than an antioxidant. The dose-response curve is not linear; more is not better. This is why NAC supplementation should always be vet-directed, at established doses, not self-prescribed at escalating levels.

The Electron Shuttle: CoQ10

You may already know CoQ10 from human heart-health supplements. Its role in veterinary cardiology is older and more established than most pet parents realise.

Coenzyme Q10 sits at the heart of the mitochondrial electron transport chain, shuttling electrons from Complex I and Complex II to Complex III. Without it, the NAD+/NADH cycle cannot complete — NADH accumulates, ATP production stalls, and cells lose their primary energy source. CoQ10 is also a potent lipid-soluble antioxidant, intercepting free radical damage to cell membranes and recycling vitamin E. Like NAD+, endogenous CoQ10 synthesis declines with age.

The editorial metaphor: NAD+ precursors without CoQ10 is like pouring fuel into an engine with a blocked distributor. The fuel arrives, but it cannot be efficiently converted into usable energy.

The Cardiology Evidence

CoQ10’s strongest veterinary evidence comes from cardiology. A 2021 randomised, double-blinded, placebo-controlled trial in dogs with myxomatous mitral valve disease (MMVD), the most common heart disease in older dogs, demonstrated that 200 mg per day of a water-soluble ubiquinone formulation produced a three-to-nearly-sevenfold increase in plasma CoQ10. A follow-up study from the same group found that supplementation reduced inflammatory markers in these dogs.

Cavalier King Charles Spaniels with congestive heart failure have been shown to have depleted myocardial CoQ10, a biochemical rationale for supplementation in a breed disproportionately affected by valve disease, and CoQ10 is also used adjunctively in veterinary oncology to protect the heart from doxorubicin-induced cardiotoxicity.

In cats, CoQ10 is widely used as an adjunct in hypertrophic cardiomyopathy (HCM), the most common feline heart disease and a condition that affects up to an estimated 15% of all cats. Feline cardiologists frequently recommend CoQ10 alongside standard cardiac medications, reasoning that the same mitochondrial energy deficit documented in human HCM applies to the thickened, energy-hungry feline myocardium. Human HCM trials have shown that CoQ10 supplementation improved diastolic function and reduced septal wall thickness over 12 to 24 months. But this practice in cats is extrapolated from human data, not from feline-specific trials. No peer-reviewed randomised controlled trial of CoQ10 in feline HCM has been published. The clinical rationale is sound; the species-specific evidence simply has not caught up.

For cat parents, the practical takeaway is that CoQ10 is considered safe and is routinely recommended by veterinary cardiologists for cats with HCM, but its benefit in cats specifically remains unproven. This is a conversation to have with your vet, not a decision to make from a supplement shelf.

Forms Matter

CoQ10 exists in two forms: ubiquinone (oxidised) and ubiquinol (reduced). Ubiquinol is the active antioxidant form and typically achieves two to four times higher plasma levels than ubiquinone in older animals with reduced reductase capacity. However, the 2021 canine MMVD trial used a properly solubilised ubiquinone formulation and still achieved therapeutic plasma levels, demonstrating that formulation quality can compensate for the theoretical ubiquinol advantage.

What does not work is powdered ubiquinone in a compressed treat. CoQ10 is lipid-soluble and requires either a lipid matrix (soft gel, MCT suspension), a solubilised formulation (water-dispersible), or the reduced ubiquinol form to achieve meaningful absorption. This is a genuinely important quality distinction that separates therapeutic from decorative supplementation.

The Fatty Acid Shuttle: L-Carnitine

Pet parents often search for: ‘L-carnitine for dogs,’ ‘carnitine heart disease dogs,’ ‘ALCAR cognitive support senior dogs,’ or ‘carnitine for cat liver.’ Here is what the evidence says.

L-carnitine is a small molecule that ferries long-chain fatty acids across the inner mitochondrial membrane via the carnitine palmitoyltransferase (CPT) system, enabling beta-oxidation, the process that converts fat into energy. Without carnitine, long-chain fats cannot reach the mitochondrial machinery. Beta-oxidation generates NADH and FADH2, the substrates that feed the electron transport chain, placing carnitine upstream of both CoQ10 and the NAD+ pool.

Heart Disease and the Grain-Free Debate

L-carnitine’s most established veterinary role is in canine dilated cardiomyopathy (DCM). Studies in American Cocker Spaniels demonstrated that taurine and L-carnitine supplementation produced measurable reversal of cardiac dysfunction. Boxer dogs with documented myocardial carnitine deficiency responded to oral supplementation. Doberman Pinschers and Great Danes feature prominently in cardiomyopathy research where carnitine is part of the nutritional management strategy.

The grain-free diet controversy of 2018–2022 brought carnitine into public awareness. Dogs fed legume-rich, grain-free, “boutique” diets developed DCM at unusual rates, and many responded to taurine and L-carnitine supplementation after diet change. The full mechanism remains incompletely understood — sulphur amino acid availability, pulse-derived bile acid sequestration, and reduced taurine synthesis all play roles — but the episode underlined that some breeds burn through carnitine faster than they can make it.

ALCAR and the Ageing Brain

Acetyl-L-carnitine (ALCAR) is the form that crosses the blood-brain barrier. A 2007 study published in the FASEB Journal found that aged Beagles receiving ALCAR combined with alpha-lipoic acid for approximately two months made significantly fewer errors on spatial-learning tasks. The combination appeared to slow mitochondrial decay in the ageing canine brain. A separate short-term study found that ALCAR alone did not improve cognition and transiently raised protein-carbonyl markers, suggesting the combination with lipoic acid matters, and that duration of supplementation is important.

Cats: Metabolic Protection

In cats, L-carnitine plays a different primary role: protecting against hepatic lipidosis, the most common form of liver failure in cats. A 2002 study published in the Journal of Nutrition demonstrated that dietary L-carnitine attenuated fasting ketosis and reduced experimental hepatic lipidosis in obese cats. Carnitine is now routinely recommended in feline weight-management protocols and during monitored weight-loss programmes, not as a “fat burner” but as metabolic insurance during caloric restriction.

Ketone Fuel for the Ageing Brain: C8/C10 MCTs

Can coconut oil help a dog with dementia? The short answer is no. But a specific fraction of coconut oil can. The distinction matters more than most pet parents realise.

As the brain ages, its ability to use glucose, its primary fuel — declines. Glucose transporters become less efficient, insulin signalling falters, and the ageing brain enters a state of energy deficit. This is well-documented in canine cognitive dysfunction syndrome (CDS) and is strikingly parallel to what happens in human Alzheimer’s disease.

Ketone bodies (specifically beta-hydroxybutyrate and acetoacetate) offer an
alternative fuel. They bypass the glucose transporters entirely, entering neurons via monocarboxylate transporters and feeding directly into the energy-production cycle. The ageing brain can use ketones even when it can no longer efficiently use glucose. This is the biological rationale behind MCT supplementation for cognitive support.

C8 (caprylic acid) and C10 (capric acid) are the medium-chain fatty acids that matter. They are absorbed via the portal vein, bypass the carnitine shuttle, and undergo rapid hepatic beta-oxidation to produce ketone bodies within 30 to 60 minutes of ingestion. C8 is the most ketogenic of the medium-chain triglycerides: gram for gram, it produces more ketones than any other dietary fat.

The Purina Beagle Trials

The strongest evidence for MCT-based cognitive support in dogs comes from a
landmark 2010 study published in the British Journal of Nutrition. Aged Beagles fed a diet supplemented with MCT (97% caprylic acid, 3% capric acid) for eight months showed significantly fewer errors across landmark discrimination, visuospatial, and attentional tasks compared to controls. Circulating ketone levels rose measurably, confirming the metabolic mechanism.

Follow-up work expanded the approach. A 2018 prospective, double-blinded, placebo-controlled trial in 87 client-owned dogs with cognitive dysfunction syndrome tested an MCT-enriched diet combined with antioxidants, B vitamins, fish oil, and arginine. Dogs on the supplemented diets showed improved behavioural scores over 90 days. This multi-nutrient approach, with MCTs as the cognitive-fuel anchor, surrounded by other neuroprotective compounds. This became the basis for commercial therapeutic diets now used in veterinary neurology.

MCTs and Cats

Cats can metabolise ketone bodies, and preliminary research from the same group has evaluated MCT-enriched diets in colony-housed senior cats. However, the dedicated feline MCT literature is substantially thinner than the canine evidence, and no large-scale feline cognitive-dysfunction trial with MCTs as the primary variable has been published. Cats are obligate carnivores with distinct lipid metabolism, and they naturally derive a higher proportion of energy from fat than dogs do. The theoretical rationale for ketone-based cognitive support applies, but the species-specific clinical evidence has not yet been generated. For cat parents interested in MCT supplementation, veterinary guidance on dosing and introduction is essential.

Why Coconut Oil Is Not MCT

This distinction matters and is widely misunderstood. Coconut oil is approximately 50% lauric acid (C12), a fatty acid that behaves more like a long-chain saturated fat than a medium-chain triglyceride. Lauric acid requires the carnitine shuttle for mitochondrial entry, is poorly ketogenic, and was not the fat used in any of the published canine cognition trials. Coconut oil contains only about 6–8% caprylic acid (C8), the compound that actually drives ketone production.

The same boundary applies to black soldier fly larvae (BSFL) fat, which is predominantly lauric acid. BSFL has a legitimate role in sustainable protein and a promising story for skin and coat health, but it cannot inherit the cognitive-support evidence generated by C8/C10 MCT research. The biology is specific to the chain length.

The Cofactor That Could Kill Your Cat: Alpha-Lipoic Acid

Pet parents often search for: ‘alpha-lipoic acid dogs,’ ‘ALA safe for cats,’ ‘lipoic acid pet supplement,’ or ‘antioxidant for senior dogs.’ Here is what the evidence says. Alpha-lipoic acid (ALA) is a uniquely versatile antioxidant, the only one that is both water-soluble and fat-soluble. It serves as an obligate cofactor for the pyruvate dehydrogenase complex, the gateway enzyme that converts pyruvate into acetyl- CoA for the TCA cycle. It recycles vitamins C and E, glutathione, and CoQ10. In its reduced form (dihydrolipoic acid), it is one of the most potent free-radical scavengers known.

In dogs, ALA has shown genuine promise for cognitive support. The 2007 FASEB Journal study that demonstrated improved spatial learning in aged Beagles used ALA in combination with acetyl-L-carnitine, the mitochondrial cofactor pairing that targets energy production and free-radical control simultaneously. It is a component of therapeutic cognitive-support diets used in veterinary neurology. Some integrative veterinarians use it off-label for diabetic neuropathy in dogs, extrapolated from a substantial human evidence base.

But ALA is lethal to cats. This is not a theoretical concern. It is a documented, peer-reviewed, dose-dependent toxicity.

The mechanism involves cats’ well-known hepatic conjugation vulnerability, the
same UGT1A6 glucuronidation deficiency that makes acetaminophen lethal, combined with pro-oxidant redox cycling at supratherapeutic concentrations and direct mitochondrial membrane permeability effects, ALA overwhelms the feline liver’s detoxification capacity at doses that would be unremarkable in a dog.

Multi-species households must take particular care. If you give ALA to your dog, store it where your cat cannot access it. A single human-dose ALA capsule, typically 300 to 600 mg, could be fatal to an average-sized cat.

The Carotenoid That Crosses the Blood-Brain Barrier: Astaxanthin

Most antioxidants cannot reach the brain. This one can. And there is a canine study that measured what happened when it got there.

Astaxanthin is a xanthophyll carotenoid — the pigment that gives wild salmon, krill, and flamingos their colour. Structurally unique among antioxidants, its polar-ended, nonpolar-centred molecule that spans the entire lipid bilayer, including mitochondrial inner membranes. It quenches singlet oxygen thousands of times more potently than vitamin C and hundreds of times more potently than vitamin E. Unlike beta-carotene, it is not converted to vitamin A in any species, which matters for cats, who cannot perform that conversion anyway.

Most importantly for this article: astaxanthin crosses the blood-brain barrier and the blood-retinal barrier, reaching neural and retinal tissues that many antioxidants cannot.

The Canine Evidence

A 2013 study published in the Journal of Animal Science directly measured the effect of astaxanthin supplementation on age-associated mitochondrial dysfunction in healthy dogs. Young and geriatric female Beagles received either 0 or 20 mg of astaxanthin daily for 16 weeks. In geriatric dogs, astaxanthin increased ATP production, increased mitochondrial mass, and increased Complex III cytochrome c oxidoreductase activity. The glutathione ratio improved in young dogs, and nitric oxide levels — a marker of oxidative stress — decreased in both age groups.

This is mechanistic evidence, not a clinical-outcome trial. It does not prove that
astaxanthin-supplemented dogs live longer or think more clearly. But it demonstrates, in a controlled setting, that oral astaxanthin reaches the mitochondria of ageing dogs and measurably improves their function. Additional canine studies have shown immune-modulating and anti-inflammatory effects at various dose levels.

In cats, no equivalent peer-reviewed clinical trial exists. Feline use is extrapolated from the canine and human data.

Source Matters — Algae, Not Krill

Astaxanthin comes from two primary sources, and the distinction has both quality and ethical dimensions. Natural astaxanthin from the freshwater microalga Haematococcus pluvialis is the form used in every published clinical trial. It is vegetarian-compatible, environmentally sustainable, and produces the trans-isomer that the body uses most efficiently.

Krill-derived astaxanthin is bound to phospholipids and has excellent bioavailability, but it is an animal-source product, derived from harvesting Antarctic krill. Synthetic astaxanthin, dominant in aquaculture feed, has a different isomer profile and lower potency per milligram.

For pet parents who care about sourcing — and our readers generally do, algae-derived astaxanthin is the evidence-supported, vegetarian-compatible, and environmentally responsible choice.

The Horizon — Emerging Interventions Worth Watching

Pet parents often search for: ‘new supplements for ageing dogs,’ ‘mitophagy for pets,’ ‘autophagy supplements dogs,’ or ‘longevity supplements for dogs 2026.’ Here is what the evidence says.

The three compounds in this section share a common profile: strong mechanistic science, growing human evidence, and essentially zero published companion-animal data. They are included here because they are genuinely promising — not because they are ready for your pet’s daily routine. The honest framing is “science to watch,” not “science settled.”

Urolithin A: Clearing Damaged Mitochondria

Urolithin A is a postbiotic — a metabolite produced by specific gut bacteria when they ferment ellagitannins from pomegranate, walnuts, raspberries, and certain berries. It induces mitophagy (the selective autophagy of damaged mitochondria), effectively clearing the cellular equivalent of broken-down vehicles from the factory floor so that new, functional mitochondria can replace them.

The human evidence is substantial. A clinical trial published in Cell Reports Medicine demonstrated that direct urolithin A supplementation improved muscle strength, exercise performance, and mitochondrial gene expression in older adults over four months. The compound also crosses the blood-brain barrier and shows preclinical neuroprotective effects.

The complication is gut-microbiome variability. Only about 40% of humans produce meaningful urolithin A from dietary ellagitannins — the rest lack the right bacterial populations. The same variability is expected in dogs and cats. This is why direct urolithin A supplementation (bypassing the microbiome entirely) is more reliable than feeding pomegranate-rich diets, though the latter has nutritional value for other reasons.

Canine data is limited to pharmacokinetic modelling and early absorption studies in Beagles. No clinical efficacy trial has been published in dogs or cats. This is a compound to discuss with a forward-thinking vet, not to self-prescribe.

PQQ: Building New Mitochondria

Pyrroloquinoline quinone (PQQ) takes a different approach to the mitochondrial problem. Where urolithin A clears damaged mitochondria, PQQ stimulates the creation of new ones — mitochondrial biogenesis — through activation of CREB phosphorylation and PGC-1α expression. A 2017 study in Biochemistry linked PQQ to increased cellular NAD+ levels and SIRT1 activation, placing it squarely at the intersection of the NAD+ and mitochondrial-biogenesis pathways.

PQQ has been proposed as a B-vitamin, but the claim remains contested — no classic dietary-deficiency syndrome has been established in mammals. It is best described as a conditional bioactive cofactor with real mechanistic effects and very limited clinical data. There are no published companion-animal studies. Small human trials show modest effects on verbal memory, reaction time, sleep quality, and markers of mitochondrial function. PQQ is often co-formulated with CoQ10, and the logic is clean — biogenesis plus electron transport — even though the combination has not been tested in dogs or cats.

Spermidine: The Autophagy Switch

Spermidine is a natural polyamine present in all eukaryotic cells. It induces autophagy — the cellular recycling process that clears damaged proteins, broken organelles, and accumulated waste, through a mechanism that is independent of the mTOR pathway (the pathway that rapamycin targets, and which Article 08 will explore in detail). It also serves as the obligate substrate for a process called hypusination of a translation factor called eIF5A, which is essential for the synthesis of mitochondrial proteins.

The foundational work, published in Nature Cell Biology in 2009, demonstrated that spermidine supplementation extended lifespan in yeast, flies, worms, and human immune cells. Subsequent studies showed cardiovascular benefits in mice and cognitive preservation in aged Drosophila and mouse models. Epidemiological studies in humans have linked higher dietary spermidine intake to lower all-cause mortality and fewer cardiovascular events.

Companion-animal evidence: essentially none. No published canine or feline trial exists.

What makes spermidine interesting from a practical perspective is its abundance in everyday foods. Wheat germ is the richest source. Aged cheese, mushrooms, soybeans, and fermented foods all carry meaningful levels. For pet parents who prefer food-first strategies, incorporating small amounts of appropriate spermidine- rich foods into their pet’s diet is a conversation worth having with their vet — though supplemental doses are a different matter entirely.

What to Discuss with Your Vet

Before you add anything from this article to your pet’s routine, there are three conversations worth having with your vet: cancer safety, drug interactions, and
supplement quality.

None of the interventions in this article should be started, changed, or stopped without a conversation with your veterinary team. This is not a legal disclaimer — it is practical advice rooted in the biology.

The Cancer Question

The most important unresolved question in NAD+ supplementation is whether boosting NAD+ in a body that also contains cancer cells might fuel those cells’
growth. Cancer cells often have high NAD+ demand — they need it for rapid DNA repair and energy production, and some preclinical studies have shown that NR supplementation modestly increased tumour growth in specific aggressive mouse models. Other studies have shown the opposite — that NAD+ precursors enhanced anti-tumour immune function.

The honest synthesis: the question is context-dependent and unresolved, and the balance between supporting healthy cellular function and potentially supporting tumour cellular function depends on tumour type, stage, and treatment context.

Polypharmacy in Senior Pets

Senior dogs and cats are often on multiple medications: pain management, cardiac drugs, thyroid medication, insulin, and behavioural medicines. Adding supplements to this mix requires awareness of interactions. The most relevant from this article: NMN and NR may improve insulin sensitivity (monitor blood glucose in diabetic pets on insulin). SAMe has a theoretical serotonin-pathway interaction with tramadol and SSRIs. NAC is inactivated by activated charcoal (separate by at least two hours in emergency contexts). ALA potentiates insulin and oral hypoglycaemics in dogs.

Quality, Form, and Storage

Throughout this article, a recurring theme is that the form of a supplement matters as much as the compound itself. Powdered ubiquinone in a treat is not the same as solubilised ubiquinone in a soft gel. Crushed SAMe is not the same as enteric-coated SAMe. Coconut oil is not the same as fractionated C8/C10 MCT oil. Quality testing, third-party verification, cool storage for NMN, and enteric coating for SAMe are not marketing features — they are the difference between a supplement that does something and one that does not.

Your vet can help you navigate these distinctions. The best supplement is the one prescribed or recommended by a veterinarian who understands your pet’s full health picture.

What Comes Next

This article has focused on the cellular energy systems that decline with age and the compounds — proven and emerging — that support them. But cellular energy is only part of the longevity conversation.

Article: Rapamycin and Autophagy explores the most studied pharmacological longevity intervention in any species — a compound originally discovered on Easter Island that is now the subject of the largest randomised controlled trial of a longevity drug in companion dogs.

Article: Light and Field Therapies moves beyond molecules entirely — into photobiomodulation, pulsed electromagnetic field therapy, and the emerging
evidence for physical therapies that support cellular repair without adding a single supplement to your pet’s routine.

Your grandmother was right. Science just took a little longer to prove it.

The fermented foods, the aged cheeses, the coconut preparations, the marine- coloured fish — traditions across cultures have been feeding their families foods rich in the very compounds modern science now studies in sterile laboratories. The molecules have names now. The mechanisms have diagrams. But the intuition was always there: that certain foods carry something the ageing body needs, even if nobody could say exactly what.

Sources Cited in This Article

1. Yoshino, J. et al. (2011). "Nicotinamide Mononucleotide, a Key NAD+ Intermediate, Treats the Pathophysiology of Diet- and Age-Induced Diabetes in Mice." Cell Metabolism, 14(4), 528–536.

2. López-Otín, C. et al. (2023). "Hallmarks of aging: An expanding universe." Cell, 186(2), 243–278.

3. Grozio, A. et al. (2019). "Slc12a8 is a nicotinamide mononucleotide transporter." Nature Metabolism, 1, 47–57.

4. Schmidt, M.S. & Brenner, C. (2019). "Absence of evidence that Slc12a8 encodes a nicotinamide mononucleotide transporter." Nature Metabolism, 1, 660–661.

5. You, Y. et al. (2020). "Subacute Toxicity Study of Nicotinamide Mononucleotide via Oral Administration." Frontiers in Pharmacology, 11, 604404.

6. Simon, A.K. et al. (2024). "A randomized, controlled clinical trial demonstrates improved owner-assessed cognitive function in senior dogs receiving a senolytic and NAD+ precursor combination." Scientific Reports, 14, 63031.

7. Cardoso, J.F.R. et al. (2023). "Replenishing NAD+ content reduces aspects of striated muscle disease in a dog model of Duchenne muscular dystrophy." Skeletal Muscle, 13, 19.

8. Tian, X. et al. (2019). "SIRT6 Is Responsible for More Efficient DNA Double-Strand Break Repair in Long-Lived Species." Cell, 177(3), 622–638.

9. Kanfi, Y. et al. (2012). "The sirtuin SIRT6 regulates lifespan in male mice." Nature, 483, 218–221.

10. Ruparell, A. et al. (2024). "Glycine supplementation can partially restore oxidative stress-associated glutathione deficiency in ageing cats." British Journal of Nutrition, 131(4), 620–631.

11. Viviano, K.R. et al. (2009). "Glutathione, cysteine, and ascorbate concentrations in clinically ill dogs and cats." Journal of Veterinary Internal Medicine, 23(2), 250–257.

12. Center, S.A. et al. (2000). "The effects of S-adenosylmethionine on clinical pathology and redox potential in the red blood cell, hepatocyte, and bile of clinically normal cats." Journal of Veterinary Internal Medicine, 14, 463–478.

13. Druzhaeva, N. et al. (2021). "Randomized, double-blinded, controlled trial of the effects of coenzyme Q10 supplementation on plasma coenzyme Q10 concentration in dogs with myxomatous mitral valve disease." American Journal of Veterinary Research, 82(4), 280–285.

14. Druzhaeva, N. et al. (2022). "Effects of Coenzyme Q10 Supplementation on Oxidative Stress Markers, Inflammatory Markers, Lymphocyte Subpopulations, and Clinical Status in Dogs with Myxomatous Mitral Valve Disease." Journal of Veterinary Internal Medicine, 36, 1936–1948.

15. Kittleson, M.D. et al. (1997). "Results of the Multicenter Spaniel Trial (MUST): Taurine- and carnitine-responsive dilated cardiomyopathy in American Cocker Spaniels." Journal of Veterinary Internal Medicine, 11(4), 204–211.

16. Blanchard, G. et al. (2002). "Dietary L-Carnitine Supplementation in Obese Cats Alters Carnitine Metabolism and Decreases Ketosis during Fasting and Induced Hepatic Lipidosis." Journal of Nutrition, 132(2), 204–210.

17. Milgram, N.W. et al. (2007). "Acetyl-L-carnitine and α-lipoic acid supplementation of aged beagle dogs improves learning in two landmark discrimination tests." FASEB Journal, 21(14), 3756–3762.

18. Pan, Y. et al. (2010). "Dietary supplementation with medium-chain TAG has long-lasting cognition-enhancing effects in aged dogs." British Journal of Nutrition, 103(12), 1746–1754.

19. Pan, Y. et al. (2018). "Efficacy of a Therapeutic Diet on Dogs With Signs of Cognitive Dysfunction Syndrome (CDS): A Prospective Double Blinded Placebo Controlled Clinical Study." Frontiers in Nutrition, 5, 127.

20. Hill, A.S. et al. (2004). "Lipoic acid is 10 times more toxic in cats than reported in humans, dogs or rats." Journal of Animal Physiology and Animal Nutrition, 88(3–4), 150–156.

21. Park, J.S. et al. (2013). "Astaxanthin modulates age-associated mitochondrial dysfunction in healthy dogs." Journal of Animal Science, 91(1), 268–275.

22. Andreux, P.A. et al. (2019). "The mitophagy activator urolithin A is safe and induces a molecular signature of improved mitochondrial and cellular health in humans." Nature Metabolism, 1, 595–603.

23. Singh, A. et al. (2022). "Urolithin A improves muscle strength, exercise performance, and biomarkers of mitochondrial health in a randomized trial in middle-aged adults." Cell Reports Medicine, 3(5), 100633.

24. Chowanadisai, W. et al. (2010). "Pyrroloquinoline Quinone Stimulates Mitochondrial Biogenesis through cAMP Response Element-binding Protein Phosphorylation and Increased PGC-1α Expression." Journal of Biological Chemistry, 285(1), 142–152.

25. Eisenberg, T. et al. (2009). "Induction of autophagy by spermidine promotes longevity." Nature Cell Biology, 11(11), 1305–1314.

26. Eisenberg, T. et al. (2016). "Cardioprotection and lifespan extension by the natural polyamine spermidine." Nature Medicine, 22(12), 1428–1438.

27. Schroeder, S. et al. (2021). "Spermidine-induced hypusination preserves mitochondrial and cognitive function during aging." Cell Metabolism, 33(4), 1–17.

28. Trammell, S.A.J. et al. (2016). "Nicotinamide riboside is uniquely and orally bioavailable in mice and humans." Nature Communications, 7, 12948.

29. Webb, C.B. et al. (2003). "S-adenosylmethionine (SAMe) in a feline acetaminophen model of oxidative injury." Journal of Feline Medicine and Surgery, 5(2), 69–75.

30. Center, S.A. (2005). "Metabolic, antioxidant, nutraceutical, probiotic, and herbal therapies relating to the management of hepatobiliary disorders." Veterinary Clinics of North America: Small Animal Practice, 34(1), 67–172.

31. Saihara, K. et al. (2017). "Pyrroloquinoline Quinone, a Redox-Active o-Quinone, Stimulates Mitochondrial Biogenesis by Activating the SIRT1/PGC-1α Signaling Pathway." Biochemistry, 56(50), 6615–6625.

32. Mostoslavsky, R. et al. (2006). "Genomic Instability and Aging-like Phenotype in the Absence of Mammalian SIRT6." Cell, 124(2), 315–329.

33. Madeo, F. et al. (2018). "Spermidine in health and disease." Science, 359(6374), eaan2788.

34. Keegan, R.F. & Webb, C.B. (2010). "Oxidative stress and neutrophil function in cats with chronic renal failure." Journal of Veterinary Internal Medicine, 24(3), 514–519.

35. Hall, J.A. et al. (2012). "Dietary medium-chain triglycerides in combination with leucine, essential fatty acids, vitamins, and antioxidants alter canine metabolomics." PLoS ONE, 7(11), e49510.

36. Massudi, H. et al. (2012). "Age-Associated Changes In Oxidative Stress and NAD+ Metabolism In Human Tissue." PLoS ONE, 7(7), e42357.

37. Pan, Y. et al. (2018). "Cognitive enhancement in old dogs from dietary supplementation with a nutrient blend containing arginine, antioxidants, B vitamins and fish oil." British Journal of Nutrition, 119(3), 349–358.